Stockscreener 앱 받기
0.726
0.89%
-0.0065
전일 마감가:
$0.7325
열려 있는:
$0.732
하루 거래량:
37,393
Relative Volume:
0.02
시가총액:
$4.22M
수익:
-
순이익/손실:
$-16.08M
주가수익비율:
-0.0211
EPS:
-34.43
순현금흐름:
$-11.54M
1주 성능:
-7.04%
1개월 성능:
-37.41%
6개월 성능:
-49.23%
1년 성능:
-91.56%
1일 변동 폭
$0.7049
$0.732
1주일 범위
$0.7049
$0.837
52주 변동 폭
$0.5933
$9.9875
Bio Path Holdings Inc Stock (BPTH) Company Profile
명칭
Bio Path Holdings Inc
전화
(832) 742-1357
주소
4710 BELLAIRE BOULEVARD, BELLAIRE, TX
BPTH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
0.7249 | 4.22M | 0 | -16.08M | -11.54M | -34.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.25 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
711.12 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
668.67 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.89 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.03 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-11 | 개시 | ROTH Capital | Buy |
| 2017-11-13 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-10 | 재확인 | Maxim Group | Buy |
| 2016-04-18 | 개시 | Rodman & Renshaw | Buy |
| 2014-06-02 | 재개 | Maxim Group | Buy |
| 2014-05-09 | 개시 | Maxim Group | Buy |
모두보기
Bio Path Holdings Inc 주식(BPTH)의 최신 뉴스
Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com - Defense World
Thyroid Cancer Drugs Market on Track of Significant Expansion by 2031 | Biovista, Vascular Biogenics, Azaya - EIN News
Bio-Path Holdings Updates Clinical Trial Data and it Sounds Promising - AccessWire
Bio-Path (BPTH) Stock Price, News & Analysis - MarketBeat
Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com - Defense World
Bio-Path Rockets To 4-Month High As Obesity Drug Shows Promise For Diabetes: Retail In Celebration Mode - MSN
Pre-market Movers: HSDT, PBM, MTEM, APTO... - RTTNews
Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com - Defense World
Bio-Path Holdings Advances Clinical Pipeline for 2025 - TipRanks
Bio-Path readies for key 2025 clinical milestones By Investing.com - Investing.com Australia
Bio-Path provides 2025 clinical, operational update - TipRanks
Bio-Path readies for key 2025 clinical milestones - Investing.com India
Bio-Path Holdings Provides 2025 Clinical and Operational Update - The Manila Times
Bio-Path's DNAbilize Platform Shows Promise in Cancer Trials, Expands to Diabetes Treatment - StockTitan
Evaxion announces plan to implement ADS ratio change - Seeking Alpha
Is This Penny Stock a Buy After a 180% Rally? - MSN
Is This Penny Stock A Buy After A 180% Rally? - Barchart
Bio-Path Holdings Advances Clinical Trials and Secures $4 Million in Funding - Citybuzz
Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com - Defense World
NoticeTEKNOSCAN SYSTEMS INC., H. SAMUEL HYAMS, PHILIP KAI-HING KUNG and SOON FOO (MARTIN) TAM, File No. 2022-19 - Barchart
Studies of Bio-path’s BP-1001-A show potential in obesity, diabetes - BioWorld Online
Bio-Path Holdings (BPTH) Surges Over 406% Following Positive Pre - GuruFocus.com
Bio-Path Holdings: Promising Preclinical Results for BP1001-A - TipRanks
MRVI Stock Drops 5% Amidst Biotech Sector Decline - GuruFocus.com
Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline - Benzinga
Bio-Path More Than Doubles on Preclinical Results of BP1001-A for Obesity - MarketWatch
Industry Leader Climet Partners with Phizzle; One of the First Joint TCO/ROI Value Proposition in Pharma Manufacturing - Newsfile
Bio-Path Holdings Shares Were On The Rise: What's Going On? - Benzinga
Gold Falls Sharply, Lamb Weston Shares Plunge - Benzinga
Innovative therapies and military tech drive early trading gains - RagingBull
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Artificial Intelligence (AI) News Live Feed - StockTitan
Wall Street-Heavily Traded - WDRB
Bio-Path (BPTH) Stock Rides High On Promising Trial Results - Stocks Telegraph
Clinical Trials News Live Feed - StockTitan
Bio-Path reports potential obesity treatment success - Investing.com
Bio-Path's Breakthrough Drug Shows Promise in Diabetes Treatment, Phase 1 Trial Set for 2025 - StockTitan
VueReal Showcases Industry-First MicroLED Design Reference Kits at CES 2025, Driving Global Innovation Across Key Industries - Newsfile
Bio-Path Holdings Faces Nasdaq Compliance and Strategic Changes - MSN
Bullfrog AI CFO Passes Away - Defense World
Rafael Holdings Reports First Quarter Fiscal 2025 Financial ResultsNEWARK, NJ – December 11, 2024 – Rafael Holdings, Inc. (NYSE: RFL) released its financial results for the first quarter of fiscal year 2025, ended October 31, 2024. The company announ - Defense World
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients - Defense World
SouthState (NASDAQ: SSB) Receives Regulatory Approvals for Merger with Independent Bank Group - Defense World
Bio-Path Holdings faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Bio-Path Holdings faces Nasdaq delisting over share price - Investing.com
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24 - The Kingston Whig-Standard
Bio-Path Holdings Shifts Focus to Metabolic Program - TipRanks
CNB Financial Services, Inc. goes ex dividend tomorrow - MSN
VueReal Highlights Revolutionary MicroLED Solutions at CES 2025 - Newsfile
Bio-Path refocuses on diabetes drug amid trial challenges By Investing.com - Investing.com South Africa
Bio Path Holdings Inc (BPTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
2.38%
자본화:
|
볼륨(24시간):